Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies
- 31 January 2002
- journal article
- editorial
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (1), 11-16
- https://doi.org/10.1016/s0959-8049(01)00340-9
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Prospective Validation of Renal Function–Based Carboplatin Dosing in Children With Cancer: A United Kingdom Children’s Cancer Study Group TrialJournal of Clinical Oncology, 2000
- Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.Journal of Clinical Oncology, 1998
- Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell supportBritish Journal of Cancer, 1996
- Calvert's formula and high-dose carboplatin.Journal of Clinical Oncology, 1994
- Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer.Journal of Clinical Oncology, 1992
- The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testisAnnals of Oncology, 1992
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Phase I studies with carboplatin at the Royal Marsden HospitalCancer Treatment Reviews, 1985
- Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum IICancer Chemotherapy and Pharmacology, 1982
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977